<DOC>
	<DOCNO>NCT02120755</DOCNO>
	<brief_summary>This research project test product call AmnioClear™ amniotic membrane graft process Liventa Bioscience formerly AFCell Medical . AmnioClear™ allograft human amniotic membrane regulate solely section 361 Public Health Service Act . The purpose study see treatment work accelerate healing time chronic wound .</brief_summary>
	<brief_title>A Randomized Comparison AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing Treatment Diabetic Wounds</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Stable Type I II diabetes mellitus At least one chronic diabetic ulcer Fullthickness ulcer size 18 cm2 . Concurrent use corticosteroid , NSAIDs immunosuppressive cytotoxic agent Bleeding disorder Ulcer muscle , tendon , capsule bone involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>